Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-11-28 Earnings Release
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2024
Earnings Release Classification · 100% confidence The document is explicitly titled "Formycon reports nine-month results for 2024" and contains detailed financial figures for the first nine months (9M/2024), including Revenue, EBITDA, and Adjusted EBITDA, along with a forecast table. This structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year. The classification 'Interim / Quarterly Report' (IR) fits this description best, as it covers nine months, which is more detailed than a simple 'Earnings Release' (ER) but not the full annual report (10-K). The document also mentions an invitation to a conference call, which often accompanies such results releases, but the core content is the financial performance report itself. 9M 2024
2024-11-28 English
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 19, 2024, announcing two main items: 1) an invitation to an earnings call for the nine-month results 2024 (which is scheduled for November 28, 2024), and 2) the company's participation schedule in various international investor conferences. Since the document is an announcement *about* an upcoming earnings call and investor meetings, rather than the full transcript of the call (CT) or the detailed quarterly report itself (IR), it fits best as an Earnings Release (ER) which often includes such forward-looking announcements, or potentially a Report Publication Announcement (RPA) if it were only announcing the release date. However, because it explicitly mentions the 'nine-month results 2024' and provides details for the associated conference call, it functions primarily as an announcement related to periodic financial results. Given the options, ER is the most appropriate fit for an announcement detailing the date/time of an earnings call for periodic results, even though it also lists investor conferences.
2024-11-19 English
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea under the tradenames AHZANTIVE and Baiama
Regulatory Filings Classification · 100% confidence The document is a press release dated November 18, 2024, announcing that Formycon AG received a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding its biosimilar candidate FYB203. It details a regulatory milestone (positive opinion leading to expected European Commission approval) for a medical product. This type of announcement, focusing on regulatory progress and key scientific/business updates outside of standard periodic financial reports (10-K, IR, ER), is best classified as a general Regulatory Announcement or a specific type of corporate news release. Since it is not a full financial report, earnings release, or a specific legal/director dealing report, and it is a formal announcement disseminated via EQS News, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant corporate news that doesn't fit other specific codes. It is not an Earnings Release (ER) as it focuses on regulatory approval status, not financial results. It is not an Audit Report (AR) or a Management Report (MDA). Given the nature of the announcement (regulatory milestone), RNS is the most appropriate fit among the available options for a non-financial, non-meeting related corporate update.
2024-11-18 English
Aflibercept-Biosimilar FYB203 / AHZANTIVE/ Baiama receives positive CHMP Opinion from EMA
Regulatory Filings Classification · 99% confidence The document is labeled as 'Ad-hoc' and contains an 'Inside Information' disclosure according to MAR Regulation (EU) No 596/2014. It announces a positive CHMP Opinion from the EMA regarding a biosimilar product (FYB203 / AHZANTIVE®/ Baiama®). This type of announcement, which is a material, non-public event disclosure mandated by EU regulation, does not fit neatly into the specific categories like 10-K, ER, or CT. It is a general regulatory announcement concerning a significant business/product development. Since it is not a specific report (like AR or IR) but a mandatory disclosure of material information, the most appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (5091 chars), but the content is purely an announcement of regulatory progress, not the full report itself.
2024-11-15 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Stimmrechtsmitteilung' (Voting Rights Notification) and explicitly mentions 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification) under German securities law (§ 40 Abs. 1 WpHG). It details changes in share ownership percentages and total voting rights for a specific shareholder (Florian Schuhbauer and related entities). This directly corresponds to the definition of reporting personal share transactions by company directors and executives, which is covered by the 'Director's Dealing' category, although the specific German filing type is a voting rights notification. Among the provided codes, 'DIRS' (Director's Dealing) is the closest fit for insider transaction reporting, even though the document is specifically a voting rights notification, which often overlaps with insider disclosure requirements when thresholds are crossed. However, since the document explicitly deals with the notification of voting rights changes, and there is no specific code for 'Voting Rights Notification' other than DVA (Declaration of Voting Results), which is for results *after* a meeting, DIRS remains the most appropriate category for insider/director transaction disclosure reporting.
2024-11-13 German
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is announcing *when* and *where* future financial reports (Quarterly/Interim statements) will be disclosed (November 28, 2024). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or is attached classifies as a Report Publication Announcement (RPA). This document is short (1787 chars) and serves only to announce the publication of the actual interim financial statements.
2024-11-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.